MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: Multicenter analysis of Japanese patients with diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2149-2154

  Kojima, Minoru ^a   Nishikii, Hidekazu ^c   Takizawa, Jun ^d   Aoki, Sadao ^e   Noguchi, Masayuki ^c   Chiba, Shigeru ^c   Ando, Kiyoshi ^a   Nakamura, Naoya ^b  

^a Division of Hematology/Oncology   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Diffuse large B cell lymphoma; MYC; Rituximab

Indexed keywords

CD5 ANTIGEN; CYCLOPHOSPHAMIDE; MYC PROTEIN; PIRARUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALGORITHM; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; JAPANESE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE REARRANGEMENT; GENES, MYC; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883875506     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.771398     Document Type: Article

References (34)

1. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: A retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol 2011; 91: 258-266.
4. Apredictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
5. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
6. Yamaguchi M, Seto M, Okamoto M, et al. D e novo CD5 + diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients. Blood 2002; 99: 815-821.
7. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-968.
8. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-1143.
9. Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322-332.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
12. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
13. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008; 22: 2226-2229.
14. Zhang HW, Chen ZW, LiS H, et al. Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma. Hematol Oncol 2011; 29: 185-189.
15. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-4925.
16. Akyurek N, Uner A, Benekli M, et al. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 2012; 118: 4173-4183.
17. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-7078.
18. Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-1607.
19. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-3537.
20. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-3365.
21. Testoni M, Kwee I, Greiner TC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol 2011; 155: 274-277.
22. Castillo JJ, Beltran BE, Song MK, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res 2012; 36: 413-417.
23. Tsurumi H, Hara T, Goto N, et al. A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. Leuk Lymphoma 2012; 53: 247-253.
24. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
25. Suzuki R, Yamamoto K, Seto M, et al. CD7 + and CD56 + myeloid/natural killer cell precursor acute leukemia: A distinct hematolymphoid disease entity. Blood 1997; 90: 2417-2428.
26. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: A clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000; 95: 2253-2261.
27. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
28. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-5502.
29. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714-723.
30. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Geneexpression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117: 4836-4843.
31. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NFkappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005; 206: 123-134.
32. Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011; 17: 7785-7795.
33. Dunleavy K, Wayne AS, Shovlin M, et al. MYC + aggressive-B-cell lymphomas: Novel therapy of untreated burkitt lymphoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol 2011; 22: Abstract 071.
34. Cuccuini W, Briere J, Mounier N, et al. MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119: 4619-4624.